UBE2D3-AS1

Across TCGA pan-cancer cohorts, UBE2D3-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of UBE2D3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where UBE2D3-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2D3-AS1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, THCA, and KIRC are the cancer types where UBE2D3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2D3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.746	<.001	8	view →
THCA	Female	All	−0.351	<.001	8	view →
KIRC	All	All	−0.204	<.001	6	view →
KICH	All	All	−0.618	<.001	5	view →
CHOL	Male	All	+1.023	<.001	4	view →
UCEC	All	All	−0.453	.002	4	view →
LUAD	All	All	+0.250	.002	4	view →
BRCA	All	All	+0.189	<.001	4	view →
BLCA	Male	IV	−0.585	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

UBE2D3-AS1–LIHC

Open the LIHC breakdown →